A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

In a significant development for pancreatic cancer treatment, a phase 1 clinical trial has highlighted the potential of ...

Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.

In a small trial, 8 of 16 patients responded well to the mRNA vaccine The vaccine is personalized, based on each patient’s ...

A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary study published Wednesday in the journal Nature. Pancreatic cancer is one ...